51. Combined Radiofrequency Ablation and Double Anti-Angiogenic Protein Therapy to Increase Coagulation Efficacy: An Experimental Study in a Murine Renal Carcinoma Model.
- Author
-
Jun HY, Ryu JH, Byun SJ, Jeong CW, Kim TH, Lee YH, and Yoon KH
- Subjects
- Adenoviridae, Animals, Carcinoma, Renal Cell blood supply, Carcinoma, Renal Cell surgery, Combined Modality Therapy, Contrast Media, Kidney Neoplasms blood supply, Kidney Neoplasms surgery, Male, Mice, Mice, Nude, Microbubbles, Neovascularization, Pathologic diagnostic imaging, Neovascularization, Pathologic surgery, Recombinant Proteins, Ultrasonography, Angiogenic Proteins antagonists & inhibitors, Carcinoma, Renal Cell therapy, Catheter Ablation methods, Kidney Neoplasms therapy, Neovascularization, Pathologic therapy
- Abstract
Objective: To evaluate whether suppression of tumor microvasculature by double anti-angiogenic protein (DAAP) treatment could increase the extent of radiofrequency ablation (RFA)-induced coagulation in a murine renal cell carcinoma model., Materials and Methods: Renal cell carcinoma cell lines were implanted subcutaneously into 10 nude mice. Four mice received adenoviral DAAP treatment and 6 mice received sterile 0.9% saline solution as DAAP-untreated group. The effect of DAAP was evaluated according to the vascularity by contrast-enhanced ultrasound (CEUS) using microbubbles. Four DAAP-treated mice and 4 DAAP-untreated mice were then treated with RFA, resulting in 3 groups: no-therapy (n = 2), RFA only (n = 4), and RFA combined with DAAP treatment (n = 4). Immediately after RFA, the size of coagulation necrosis and mitochondrial enzyme activity were compared between the groups using analysis of variance (ANOVA) and post hoc test., Results: The contrast enhancement ratio for tumor vascularization on CEUS was significantly lower in the DAAP treated group than in DAAP-untreated group (30.2 ± 9.9% vs. 77.4 ± 17.3%; p = 0.021). After RFA, the mean coagulation diameter was 0 mm for no-therapy group, 6.7 ± 0.7 mm for the RFA only group and 8.5 ± 0.4 mm for the RFA with DAAP group (ANOVA, p < 0.001). The area of viable mitochondria within the tumor was 27.9 ± 3.9% in no-therapy group, 10.3 ± 4.5% in the RFA only group, and 2.1 ± 0.7% in the RFA with DAAP group (ANOVA, p < 0.001)., Conclusion: Our results suggest the potential value of combining RFA with anti-angiogenic therapy.
- Published
- 2015
- Full Text
- View/download PDF